Angiotensin II and growth factors in the pathogenesis of diadirectly or through generation of other mediators, inbetic nephropathy. The renin-angiotensin system (RAS) and cluding growth factors [1][2][3][4][5][6][7][8][9]. Here, we summarize certain growth factors mediate structural and functional changes duraspects of the role of the RAS and growth factors in DN.
However, components of RAS also are expressed in Their effects are likely modulated by metabolic changes including high glucose and free fatty acids. While blockade of the many tissues where Ang II is generated locally [10] [11] [12] [13] .
RAS ameliorates DN in humans, such evidence for blockade
Non-ACE pathways of Ang II generation exist and inof growth factors is still lacking. It is likely that susceptibility clude chymostatin Ang II generating enzyme (CAGE), to the development of DN and therapeutic efficacy are moduserine proteinase chymases, tissue plasminogen activalated by genetic polymorphisms in components of the RAS tor, cathepsin G and tonin [2, 7] . In the human kidney, and growth factors including their receptors and other target molecules. Approaches to understand the intricate relationship virtually all Ang I generation is renin-dependent, but between these systems and the mechanism(s) by which they nearly 40% of Ang I may be converted to Ang II by alter capillary permeability and result in structural changes are pathways other than ACE. The contribution of non-ACE areas of fruitful investigation.
pathways to Ang I and Ang II generation may be substantially augmented in diabetes mellitus (DM) [2, 3, 12] . Hyperglycemia, elevated free fatty acids, and decreased There is evidence that angiotensin II (Ang II) and (type 1 DM) or increased (type 2 DM) levels of insulin growth factors play a role in mediating the hemodynamic may regulate RAS in the kidney. However, direct eviand structural/metabolic manifestations of diabetic nedence for activation of local RAS in DN is still lacking phropathy (DN) [1] . In humans and experimental animals [2, 3] . ACE immunostaining is increased in glomeruli with DN, angiotensin converting enzyme inhibitors (ACEI) and may be decreased in proximal tubules in advanced and angiotensin receptor blockers (ARBs) decrease glo-DN. The effects of Ang II in DN are mediated via activamerular injury, by decreasing systemic blood pressure tion of two of its receptors, AT 1 and AT 2 , the former and glomerular capillary pressure [1] [2] [3] . In glomerular, being the predominant form. Renal expression of both tubular and interstitial cells, Ang II induces protein synthereceptors is down-regulated in DN [6] . However, the sis, hypertrophy, proliferation and matrix expansion, sugenhanced sensitivity to Ang II or to Ang II blockade in gesting non-hemodynamic mechanisms of Ang II-induced DN suggests that AT 1 -mediated signaling is regulated injury [2, 3] . As DN is characterized by low circulating by other mediators such as nitric oxide (NO) [6] . Differrenin, activation of local renal renin-angiotensin system (RAS) has been incriminated in renal injury [2, 3] There is indirect evidence that Ang II alters the pro-NAD(P)H oxidases remains unexplored. tein assembly of the podocyte slit diaphragm thereby regulating the glomerular capillary permselectivity. How-GROWTH FACTORS ever, the role of slit diaphragm/podocyte proteins in DN Expression of several growth factors and cytokines is has not been fully explored. In rats with spontaneous increased in DN and the biological activity of growth proteinuria, zonula occludens-1 (ZO-1), an important confactors may be altered in diabetes. Renal TGF-␤ expresstituent of the podocyte foot process, is redistributed from sion is increased in both type 1 and type 2 diabetes [8, 22] . its normal membrane location to the cytoplasm. AdminisPutative factors that regulate TGF-␤ expression include tration of ACEI prevents both glomerular redistribution hyperglycemia, advanced glycated end-products (AGEs), of ZO-1 and proteinuria, suggesting a role for Ang II in mechanical stretch, Ang II, endothelin, lipids and prodregulation of glomerular permselectivity [15] . Moreover, ucts of oxidative stress [1] . High glucose concentration diabetic SHR develop a deficiency of nephrin, which is increases TGF-␤-1 expression and activity in mesangial restored by the use of the ARB irbesartan with attenuaand proximal tubular epithelial cells that is dependent on tion of albuminuria [16] . In another model of nephrosis, local RAS activation [4, 14] . TGF-␤ is a potent fibrogenic progressive renal injury was associated with down-regufactor that modulates synthesis of both matrix proteins lation of nephrin, which was totally prevented both by [5] and their receptors such as integrins and osteopontin. an ACEI and an ARB, suggesting that Ang II plays a TGF-␤ also contributes to the apoptosis of podocytes. role in modulating nephrin expression [17] . Furthermore,
In db/db mice treated chronically with anti-TGF-␤ antiin an experimental model of DN, there is a decrease in bodies, renal function and structure are preserved but the number of slit pores per unit length of glomerular proteinuria persists [23] . Thus, at least in this model, it basement membrane, indicative of podocyte foot-proappears that TGF-␤ contributes to the structural changes cess broadening. Both an ACEI and an ARB attenuated but not to the increased glomerular permeability. these ultrastructural changes, suggesting that preservaConnective tissue growth factor (CTGF) is another tion of podocyte architecture could contribute to the pro-sclerotic cytokine with increased renal and glomerurenoprotective effects of blockade of the RAS in DN [18] . lar expression in DN. Synthesis of CTGF is stimulated The mechanism by which the diabetic environment by TGF-␤, hyperglycemia, AGEs, mechanical stretch, modulates the responses to Ang II remains largely unexand CTGF itself [1] . Vascular endothelial growth factor plored. The hyperglycemic environment may potentiate (VEGF) is a cytokine highly expressed in the kidney, the trophic effects of Ang II, likely via additive effects primarily in podocytes but also in distal tubules and on protein kinase C (PKC) activation and expression of collecting ducts, with its major receptor, type 2 VEGF transforming growth factor ␤ (TGF-␤) [5, 6] . Ang II and receptor, expressed on endothelial cells and cortical fihigh glucose have costimulatory actions on platelet-derived broblasts [24] . VEGF may contribute to the hemodygrowth factor (PDGF) and TGF-␤ production, as well as namic events in DN as anti-VEGF antibodies attenuate on the accumulation of extracellular matrix components. albuminuria and hyperfiltration [25] . Preliminary obserAng II and high glucose also inhibit intracellular proteinvations show that VEGF is augmented in renal cortex ases in proximal tubules and nitric oxide synthase (NOS) of mice in early stages of type 1 or type 2 DM, coinciding expression [5] . In vascular smooth muscle cells, high gluwith hypertrophy (abstract; Senthil et al, J Am Soc cose concentrations augment Ang II-induced JAK/ Nephrol 12:566A-567A, 2001). Another growth factor, STAT and ERK1/2 type mitogen-activated protein kiinsulin-like growth factor I (IGF-I), may play an impornase activation [19] . In addition, there is a growing body tant role in the early development of renal hypertrophy of evidence suggesting that Ang II-induced generation in DN. Octreotide, an inhibitor of somatostatin, reduces of reactive oxygen species play a critical role in the hyperkidney IGF-I expression and ameliorates renal hypertrotrophy and the matrix accumulation associated with DN. phy and albuminuria [26] . Growth hormone may contribIn mesangial cells, Ang II activates the hypertrophic serine-threonine kinase Akt/protein kinase B via a reute directly or via IGF-I to the renal hypertrophy in DN,
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Much work is needed to elucidate molecular mechanisms by which these mediators regulate structure and function of renal cells in diabetes.
The observation that many patients with DN continue to progress to end-stage renal disease despite therapy including blockade of the RAS is a rationale to continue to explore the role of Ang II and growth factors in diabetic renal disease. Growth factor expression is not exclusively dependent on the RAS. Moreover, current drug dosage regimens use blood pressure control as the target, and there is poor documentation of blockade of tissue RAS. The regulation of renal tissue RAS components in diabetes remains largely unexplored. Mice deficient in tissue ACE or other components of the RAS may over, the role of a novel ACE homolog and biologically active metabolites of Ang I in diabetic end organ complications awaits investigation. Translational studies in humans to block deleterious effects of growth factors need as shown by a lesser degree of renal hypertrophy in to be explored, after thorough understanding of signaling growth hormone-deficient mice with type 1 DM. There is evidence IGF-I mediates hypertrophy in cultured mesmolecules that mediate these effects. This will facilitate angial cells via a calcineurin-dependent pathway [27] .
development of selective and safe inhibitors. There is genetic heterogeneity not only in the susceptibility to AGEs and oxidative stress DN, but also in responsiveness to drugs that block the In DM, increased non-enzymatic glycation leads to RAS. Reproducible studies to explore genetic polymorformation of lipoxidation and glycoxidation products phisms in components of the RAS, growth factors and that increase the expression of growth factors. AGE their receptors are needed. inhibitors, aminoguanidine and OPB-9195, attenuate increased expression of TGF-␤, PDGF and VEGF, and ACKNOWLEDGMENTS accumulation of ECM in DN [28, 29] role in the pathogenesis of human DN [31] .
In addition to regulating their expression, Ang II may REFERENCES modulate signal transduction pathways activated by growth factors, providing a potential mechanism by which the RAS 1. Cooper ME: Interactions of metabolic and haemodynamic factors may contribute to the pathogenesis of DM and its compliin mediating experimental diabetic nephropathy. Diabetologia 44:1957-1972, 2001 cations. For instance, by directly interfering with insulin to be regulated by Ang II and growth factors (Fig. 1) .
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